-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Cytoreduction for ET and PV: Who, What, When, and How?

Program: Education Program
Session: What Are the Advances in Myeloproliferative Neoplasms Affecting Management?
Hematology Disease Topics & Pathways:
Research, clinical trials, epidemiology, Clinical Practice (Health Services and Quality), MPN, Clinical Research, health outcomes research, Chronic Myeloid Malignancies, Diseases, real-world evidence, Therapies, therapy sequence, Myeloid Malignancies
Sunday, December 10, 2023, 9:30 AM-10:45 AM

Douglas Tremblay, MD

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

Disclosures: Tremblay: Astellas Pharma: Research Funding; CTI Biopharma: Consultancy, Research Funding; Novartis: Consultancy; GSK: Consultancy; Sierra Oncology: Consultancy; Cogent Biosciences: Consultancy; AbbVie: Consultancy; Gilead: Research Funding.

See more of: What Are the Advances in Myeloproliferative Neoplasms Affecting Management?
See more of: Education Program
Previous Presentation | Next Presentation >>